NCT02337686View on ClinicalTrials.gov

Pembrolizumab in Treating Patients With Recurrent Glioblastoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 28, 2015

Primary Completion Date

May 24, 2017

Study Completion Date

December 31, 2026

Conditions
Recurrent GlioblastomaRecurrent Gliosarcoma
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Pembrolizumab

Given IV

OTHER

Pharmacological Study

Correlative studies

PROCEDURE

Therapeutic Conventional Surgery

Undergo surgery

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER